Yuchen Ding
Jefferies LLC, Research Division

Welcome to the Jefferies Healthcare Conference. My name is Dennis Ding, Biotech Research Analyst here at Jefferies. I have the great pleasure of having Matt Gline here, CEO of Roivant. Welcome.

Matthew Gline
CEO & Director

Thanks for having me. It's great to be here.

Yuchen Ding
Jefferies LLC, Research Division

Before we kind of get into Q&A, and there is certainly lots to talk about, I'd love to hand it over to you to just kind of give an overview. I mean it's been incredibly -- I mean, Roivant is a $20 billion market cap company now.

Matthew Gline
CEO & Director

It's true. It's a while -- look, it's been a really great 12 months for us. Look, I think many of you know a little bit about our story, but we are roughly out there trying to do the same thing everybody else is, which is to develop medicines that matter. And we've been very fortunate to have now 3 drugs in our late-stage pipeline and brepocitinib, IMVT-1402, our FcRn and mosliciguat, all of which appear to be drugs that matter.

We have our first sort of major commercial launch, certainly our first next commercial launch in brepocitinib in dermatomyositis, which should be by the end of September, assuming everything goes along as expected with FDA, a bunch more data coming later this year and all that building on top of positive data in DM, in cutaneous sarcoidosis, in D2T RA at Immunovant, all sort of in the recent history. So just a ton going on, a ton we're excited about and a really great